Identification of FDA-approved oncology drugs with selective potency in high-risk childhood ependymoma.

Children with ependymoma (EPN) are cured in less than 50% of cases, with little improvement in outcome over the last several decades. Chemotherapy has not impacted survival in EPN, due in part to a lack of preclinical models that has precluded comprehensive drug testing. We recently developed two hu...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Mol Cancer Ther
Glavni autori: Donson, Andrew M., Amani, Vladimir, Warner, Elliot A., Griesinger, Andrea M., Witt, Davis A., Levy, Jean M. Mulcahy, Hoffman, Lindsey M., Hankinson, Todd C, Handler, Michael H., Vibhakar, Rajeev, Dorris, Kathleen, Foreman, Nicholas K.
Format: Artigo
Jezik:Inglês
Izdano: 2018
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6125158/
https://ncbi.nlm.nih.gov/pubmed/29925527
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-1185
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items